Top

Diagnostic Pathology

Published in:

Open Access 01-12-2015 | Research

Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia

Authors: Li Liu, Ren’an Chen, Yangping Zhang, Wen Fan, Fang Xiao, Xueqian Yan

Published in: Diagnostic Pathology | Issue 1/2015

Abstract

Background

Dysregulation of circulating miR-328 has been identified in several tumors and is associated with prognosis of patients. However, the expression pattern of miR-328 and the impact on prognosis has not yet been studied in acute myeloid leukemia (AML). The purpose of this study is to investigate the expression status of miR-328 and its clinical significance in AML patients.

Methods

RNA was extracted from plasma of 176 patients with newly diagnosed AML and 70 healthy volunteers. The miR-328 expression was examined by Realtime quantitative PCR. The association of circulating miR-328 expression with clinicopathological factors and prognosis of AML patients was statistically analyzed.

Results

The expression of miR-328 was significantly downregulated in AML patients (median value 22.99, range: 3.63-242.0) compared with those of healthy controls (median value 89.17, range: 12.05-397.7; P < 0.001), and miR-328 expression was markedly increased in patients after treatment than before (23.40 ± 1.76 vs. 46.61 ± 3.83, P < 0.001). Moreover, low levels of miR-328 were associated with a higher white blood cell count and BM blast count (P = 0.026 and P = 0.003, respectively), and lower hemoglobin and platelet count (P = 0.004 and P = 0.022, respectively). Patients with low miR-328 expression had a relatively poor overall survival (P = 0.022) and shorter relapse-free survival (P = 0.008) than those with high miR-328 expression. In addition, low miR-328 expression was an independent prognostic factors for both OS (P = 0.017) and RFS (P = 0.023).

Conclusions

Circulating miR-328 downregulation is a common event and is associated with poor clinical outcome in AML patients.

Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484–95. doi:10.1016/S0140-6736(12)61727-9.PubMedCrossRef

Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014;15(9):e382–94. doi:10.1016/S1470-2045(14)70008-7.PubMedCrossRef

Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009;2:23. doi:10.1186/1756-8722-2-23.PubMedCentralPubMedCrossRef

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.PubMedCrossRef

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMedCrossRef

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8. doi:10.1038/nature03702.PubMedCrossRef

Takada S, Yamashita Y, Berezikov E, Hatanaka H, Fujiwara SI, Kurashina K, et al. MicroRNA expression profiles of human leukemias. Leukemia. 2008;22(6):1274–8. doi:10.1038/sj.leu.2405031.PubMedCrossRef

Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol (Dordr). 2012;35(5):317–34. doi:10.1007/s13402-012-0095-3.CrossRef

Sun SM, Rockova V, Bullinger L, Dijkstra MK, Dohner H, Lowenberg B, et al. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. 2013;27(1):100–6. doi:10.1038/leu.2012.158.PubMedCrossRef

10.

Chen XX, Lin J, Qian J, Qian W, Yang J, Ma JC, et al. Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem. 2014;47(1–2):63–6. doi:10.1016/j.clinbiochem.2013.09.020.PubMedCrossRef

11.

Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012;119(10):2314–24. doi:10.1182/blood-2011-10-386235.PubMedCentralPubMedCrossRef

12.

Li Y, Lin J, Yang J, Qian J, Qian W, Yao DM, et al. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leuk Res. 2013;37(12):1642–7. doi:10.1016/j.leukres.2013.09.022.PubMedCrossRef

13.

Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011;12(5):1117–25.PubMed

14.

Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One. 2011;6(6), e20769. doi:10.1371/journal.pone.0020769.PubMedCentralPubMedCrossRef

15.

Cheng G. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81C:75–93. doi:10.1016/j.addr.2014.09.001.CrossRef

16.

Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140(5):652–65. doi:10.1016/j.cell.2010.01.007.PubMedCentralPubMedCrossRef

17.

Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W, et al. MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One. 2012;7(10), e47270. doi:10.1371/journal.pone.0047270.PubMedCentralPubMedCrossRef

18.

Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, et al. Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. Int J Mol Sci. 2013;14(5):10332–42. doi:10.3390/ijms140510332.PubMedCentralPubMedCrossRef

19.

He F, Lv P, Zhao X, Wang X, Ma X, Meng W, et al. Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem. 2014;394(1–2):137–44. doi:10.1007/s11010-014-2089-0.PubMedCrossRef

20.

Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. France: IARC Press. 2008;2008.

21.

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620–5.PubMedCrossRef

22.

Lo Coco F, Foa R. Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. Eur J Haematol. 1995;55(1):1–9.PubMedCrossRef

23.

Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–83.PubMed

24.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.PubMedCrossRef

25.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.PubMedCrossRef

26.

Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014;24(16):R762–76. doi:10.1016/j.cub.2014.06.043.PubMedCrossRef

27.

Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol. 2012;138(4):671–4. doi:10.1007/s00432-012-1147-9.PubMedCrossRef

28.

Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL. Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol. 2014;20(22):6906–11. doi:10.3748/wjg.v20.i22.6906.PubMedCentralPubMedCrossRef

29.

Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 2013;11:31. doi:10.1186/1479-5876-11-31.PubMedCentralPubMedCrossRef

30.

Yuan J, Zheng Z, Zheng Y, Lu X, Xu L, Lin L. microRNA-328 is a favorable prognostic marker in human glioma via suppressing invasive and proliferative phenotypes of malignant cells. Int J Neurosci. 2015:1–22. doi:10.3109/00207454.2014.1002610.

31.

Chen CH, Cheng CY, Chen YC, Sue YM, Liu CT, Cheng TH, et al. MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis. PLoS One. 2014;9(6), e99802. doi:10.1371/journal.pone.0099802.PubMedCentralPubMedCrossRef

Title: Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia
Authors: Li Liu
Ren’an Chen
Yangping Zhang
Wen Fan
Fang Xiao
Xueqian Yan
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-015-0345-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Expression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma

Intravascular NK-cell lymphoma: a case report and review of the literature

Intrahepatic bile duct mixed adenoneuroendocrine carcinoma: a case report and review of the literature

Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential

The percentage of lepidic growth is an independent prognostic factor in invasive adenocarcinoma of the lung

Alveolar soft part sarcoma of lung: report of a unique case with emphasis on diagnostic utility of molecular genetic analysis for TFE3 gene rearrangement and immunohistochemistry for TFE3 antigen expression